Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 14 2025
0mins
Source: Globenewswire
Virtual Investor Forum Availability: Presentations from the Life Science Virtual Investor Forum held on March 13 are now available for online viewing for 90 days, allowing investors to access company materials and schedule one-on-one meetings until March 18.
About Virtual Investor Conferences: Virtual Investor Conferences (VIC) is a leading platform that facilitates direct presentations from publicly traded companies to investors, enhancing engagement through interactive features and targeted meeting scheduling.
Analyst Views on CGTX
Wall Street analysts forecast CGTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CGTX is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.460
Low
3.00
Averages
3.00
High
3.00
Current: 1.460
Low
3.00
Averages
3.00
High
3.00
About CGTX
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. The Company is investigating its lead candidate, zervimesine (CT1812), in clinical programs in dementia with Lewy bodies (DLB) and Alzheimer’s disease. Its CT1812 and pipeline of sigma-2 modulators can regulate pathways that are impaired in these diseases for the treatment of degenerative diseases. Its lead product candidate, CT1812, is an orally delivered, small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins. Its pipeline candidates were discovered using proprietary biology and chemistry platforms designed to identify novel drug targets and disease-modifying therapies that address dysregulated pathways. It is developing other product candidates in the area of synucleinopathies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
